These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 23877657)
1. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma. Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657 [TBL] [Abstract][Full Text] [Related]
2. Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stress-induced cell death. Naradun N; Talabnin K; Ayuttha KIN; Talabnin C Naunyn Schmiedebergs Arch Pharmacol; 2023 Jan; 396(1):109-120. PubMed ID: 36227332 [TBL] [Abstract][Full Text] [Related]
5. Diethyldithiocarbamate suppresses an NF-kappaB dependent metastatic pathway in cholangiocarcinoma cells. Srikoon P; Kariya R; Kudo E; Goto H; Vaeteewoottacharn K; Taura M; Wongkham S; Okada S Asian Pac J Cancer Prev; 2013; 14(7):4441-6. PubMed ID: 23992017 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583 [TBL] [Abstract][Full Text] [Related]
8. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661 [TBL] [Abstract][Full Text] [Related]
9. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588 [TBL] [Abstract][Full Text] [Related]
10. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985 [TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response. Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979 [TBL] [Abstract][Full Text] [Related]
12. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Prakobwong S; Gupta SC; Kim JH; Sung B; Pinlaor P; Hiraku Y; Wongkham S; Sripa B; Pinlaor S; Aggarwal BB Carcinogenesis; 2011 Sep; 32(9):1372-80. PubMed ID: 21325634 [TBL] [Abstract][Full Text] [Related]
13. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma. Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281 [TBL] [Abstract][Full Text] [Related]
14. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885 [TBL] [Abstract][Full Text] [Related]
15. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771 [TBL] [Abstract][Full Text] [Related]
17. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ Cancer Res; 2005 Dec; 65(24):11510-9. PubMed ID: 16357160 [TBL] [Abstract][Full Text] [Related]
19. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Gu H; Chen X; Gao G; Dong H Mol Cancer Ther; 2008 Aug; 7(8):2298-307. PubMed ID: 18723477 [TBL] [Abstract][Full Text] [Related]
20. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells. Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]